NCT05840107View on ClinicalTrials.gov

Study of FasT CAR-T GC012F Injection NDMM Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 4, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

GC012F injection

GC012F injection is an autologous dual CAR-T targeted BCMA and CD19. A single infusion of CAR-T cells will be administered intravenously

Trial Locations (1)

200003

RECRUITING

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
collaborator

Gracell Biotechnologies (Shanghai) Co., Ltd.

INDUSTRY

lead

Shanghai Changzheng Hospital

OTHER